Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is supported by a de-risked intellectual property and development backdrop after settling litigation with Nerviano and amending the 2017 Exclusive License Agreement, which secures global rights around onvansertib and reduces the chance of competitive encroachment during the royalty term. Its lead asset is backed by compelling clinical signal in the ongoing CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer, where 30mg onvansertib with FOLFIRI plus bevacizumab produced a 72.2% ORR versus 42.1% in control and median PFS was not reached versus about 11 months. The combination of a validated PLK1 target, manageable safety profile, and upcoming ASCO data presentation strengthens the investment case by increasing the probability of broader clinical and commercial value.

Cardiff Oncology is facing a major fundamental setback after Nerviano Medical Sciences terminated the onvansertib license agreement on May 27, 2026, citing alleged material breaches tied to inventorship corrections and failure to use commercially reasonable efforts. The dispute threatens the company’s core asset by putting regulatory communications, development data, and oversight of ongoing trials at risk, which could materially disrupt the Phase 2 program in RAS-mutated metastatic colorectal cancer. With Cardiff still a clinical-stage biotechnology company dependent on a single lead program and now entangled in Case No. 3:26-cv-3131-RBM-JLB, the outlook is weakened by heightened legal uncertainty and potential loss of control over its most important pipeline asset.